DYSLIPIDEMIA IN PATIENTS WITH DIABETES: ETIOLOGY AND MANAGEMENT

Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increase in triglyceride level, decrease in high-density lipoprotein-cholesterol levels and increase in small dense low-density lipoprotein (LDL) particles. It is most common to have dyslipidemia in type 2 diabetic patients and it affects 70% of the patients. Diabetis is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) which is one most common reasons of death in many countries. In this review we have discussed several pharmacological and non paharmacological treatment modalities including several trials which had positive effects on cardiovascular events in patients who has diabetes. ASCVD is is reduced in patients by lowering the LDL-C levels by 30 to 45 % usinf statin therapy. Other therapies like Ezetimibe, pcsk9, has shown posititve effects on loweing LDL-C levels and ASCVD event reduction.